SCHEMBL6071585

SCHEMBL6071585

COc1cccc(NN)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.48
GRM5 P41594 1/20 0.45
KDR P35968 1/20 0.45
TRPV4 Q9HBA0 1/20 0.40
HDAC1 Q13547 1/20 0.39
SORT1 Q99523 1/20 0.39
SIRT2 Q8IXJ6 1/20 0.38
SIRT1 Q96EB6 1/20 0.38
NNMT P40261 1/20 0.38
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38
TYK2 P29597 1/20 0.38
JAK3 P52333 1/20 0.38
BTK Q06187 1/20 0.38
GOT1 P17174 1/20 0.38
MAPK8 P45983 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2468863 0.81 GRM5 (0.46) TAAR1GRM5KDRTRPV4HDAC1
Hydrochloric Acid SCHEMBL2942831 0.79 GRM5 (0.45) TAAR1GRM5KDRTRPV4HDAC1
SCHEMBL6342929 0.79 MAPK8 (0.61) GRM5BTKMAPK8KDM4EMEN1
SCHEMBL24129488 0.78 GRM5 (0.44) TAAR1GRM5KDRTRPV4HDAC1
SCHEMBL160602 0.77 BTK (0.47) GRM5KDRBTKKDM4EMEN1
SCHEMBL10829377 0.76 TAAR1 (0.49) TAAR1GRM5KDRTRPV4SORT1
SCHEMBL8348068 0.76 GRM5 (0.50) TAAR1GRM5KDRTRPV4HDAC1
SCHEMBL5029541 0.76 NR3C2 (0.53) GRM5HDAC1SORT1NNMTJAK2
SCHEMBL16571729 0.76 SORT1 (0.43) TAAR1GRM5KDRHDAC1SORT1
SCHEMBL6642586 0.76 TAAR1 (0.49) TAAR1GRM5KDRTRPV4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4745134-A1 PROTEIN ARGINASE METHYLTRANSFERASE-5 INHIBITOR AND MEDICAL USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2026-05-20 EP disclosed
CN-119698412-A 5-HT2A receptor agonist, and preparation method and application thereof 上海翊石医药科技有限公司 2025-03-25 CN disclosed
WO-2025021120-A1 5-HT2A RECEPTOR AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海翊石医药科技有限公司 2025-01-30 WO disclosed
WO-2025016323-A1 PROTEIN ARGINASE METHYLTRANSFERASE-5 INHIBITOR AND MEDICAL USE THEREOF 江苏亚虹医药科技股份有限公司 2025-01-23 WO disclosed
US-20230227453-A1 TRICYCLIC PSYCHOPLASTOGENS AND USES THEREOF DELIX THERAPEUTICS, INC. 2023-07-20 US disclosed
US-20230227453-A1 TRICYCLIC PSYCHOPLASTOGENS AND USES THEREOF DELIX THERAPEUTICS, INC. 2023-07-20 US disclosed
US-20230227453-A1 TRICYCLIC PSYCHOPLASTOGENS AND USES THEREOF DELIX THERAPEUTICS, INC. 2023-07-20 US disclosed
CN-116438180-A Tricyclic neural plasticizers and uses thereof 德力克斯疗法有限公司 2023-07-14 CN disclosed
EP-4165042-A1 TRICYCLIC PSYCHOPLASTOGENS AND USES THEREOF Delix Therapeutics, Inc. (US) 2023-04-19 EP disclosed
US-11339130-B1 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2022-05-24 US disclosed
US-20090036481-A1 Novel Azaindole Inhibitors of Mtp and Apob MERCK PATENT GMBH (DE) 2009-02-05 US disclosed
US-20060167020-A1 Pyrazolopyrimidines as kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2006-07-27 US disclosed
US-6949648-B2 Condensed pyrazole derivatives, process for producing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-09-27 US disclosed
EP-1523314-A2 PYRAZOLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS SmithKline Beecham Corporation (US) 2005-04-20 EP disclosed
WO-2004009597-A2 PYRAZOLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-01-29 WO disclosed
US-20030187014-A1 Condensed pyrazole derivatives, process for producing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-10-02 US disclosed
EP-1270572-A1 CONDENSED PYRAZOLE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-01-02 EP disclosed
US-6248305-B1 ESTROGEN SENSITIVE DISEASES, CANCER SRI INTERNATIONAL 2001-06-19 US disclosed
US-6083936-A TREATMENT OF ESTROGEN-DEPENDENT DISORDERS SUCH AS ESTROGEN-DEPENDENT CANCERS; ALSO USEFUL IN DIAGNOSTIC TECHNIQUES SUCH AS MAGNETIC RESONANCE IMAGING AND MAGNETIC RESONANCE SPECTROSCOPY SRI INTERNATIONAL (US) 2000-07-04 US disclosed
US-4315982-A Styryl pyrazoline compounds, process for production thereof, and electrophoto graphic material comprising said compounds COPYER CO., LTD. (JP) 1982-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227453-A1 TRICYCLIC PSYCHOPLASTOGENS AND USES THEREOF GAP43, GRIN2A, GRIN2C TAAR1 143/4885GRM5 36/4885KDR 4732/4885
US-20090036481-A1 Novel Azaindole Inhibitors of Mtp and Apob APOB, MTPN, HDLBP TAAR1 2907/4885GRM5 3096/4885KDR 3335/4885
US-20060167020-A1 Pyrazolopyrimidines as kinase inhibitors MAP3K12, MAP3K5, MAP3K2 TAAR1 4276/4885GRM5 2137/4885KDR 739/4885
US-11339130-B1 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 TAAR1 4758/4885GRM5 1467/4885KDR 4332/4885
US-20030187014-A1 Condensed pyrazole derivatives, process for producing the same and use thereof PTGS1, PTGIS, IL5 TAAR1 3606/4885GRM5 2695/4885KDR 4339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.